Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion-Positive NSCLC Real-World Cohort: A Brief Report
{{output}}
Introduction: RET fusion-driven NSCLC accounts for 2% of advanced lung adenocarcinomas, and selective RET tyrosine kinase inhibitors (RETis) are the current first-line standard-of-care treatment. However, acquired resistance to R... ...
